NSCLC's prescriber base is concentrated, specialist, and biomarker-gated, the opposite of a primary-care market — so field strategy is account depth, not prescriber reach.
NSCLC is prescribed almost entirely by medical and hematology-oncologists, a concentrated specialist base of roughly 13,000 practicing US oncologists (ASCO oncology-workforce data) clustered in academic cancer centers and large community-oncology networks (US Oncology, OneOncology, and similar). Volume concentrates further within that base: a minority of high-volume thoracic-oncology accounts drives the majority of eligible patients, so the addressable target list is small and identifiable, and the commercial question is account penetration and depth, not breadth of reach.
Two structural facts set the field model. First, channel: infused immuno-oncology and chemotherapy are buy-and-bill under Medicare Part B (the practice acquires and is reimbursed), while oral targeted agents (EGFR, ALK, ROS1, KRAS-G12C) route through Part D — so field roles must cover both the practice-economics/site-of-care conversation and the pharmacy-access one. Second, targeting is biomarker-gated: EGFR/ALK/ROS1/PD-L1 testing determines eligibility, so the field and MSL effort centers on driving comprehensive biomarker testing and positioning within the tested subpopulation. The result is a small, account-based key-account-manager + medical-science-liaison model with long, relationship-led cycles, structurally different from a primary-care field force.
The NSCLC commercial-field structure — a specialist, account-based model driven by prescriber concentration and channel.
| Dimension | NSCLC (specialist / buy-and-bill) | Source / basis |
|---|---|---|
| Prescriber universe | ~13,000 medical/hematology-oncologists; concentrated, identifiable target list | ASCO oncology-workforce estimate |
| Account structure | Academic cancer centers + large community-oncology networks (US Oncology, OneOncology); volume concentrated in high-volume thoracic accounts | Practice-network landscape |
| Reimbursement channel | Buy-and-bill Medicare Part B (infused IO/chemo); Part D for oral targeted agents | CMS Part B / Part D |
| Targeting gate | Biomarker-gated: EGFR / ALK / ROS1 / PD-L1 testing determines eligibility | NCCN NSCLC guideline |
| Field model | Account-based KAM + MSL; long, relationship-led cycles; depth over reach | Framework (specialist-oncology archetype) |
| Incentive-comp basis | Account-level, longer cycle; testing-rate and site-of-care metrics alongside volume | Framework |
Sources: Prescriber base: ASCO oncology-workforce estimates (~13,000 practicing US oncologists/hematologists). Channel: CMS Medicare Part B (buy-and-bill for physician-administered IO/chemo) vs Part D (oral targeted agents). Biomarker gating: NCCN Clinical Practice Guidelines in Oncology — NSCLC (EGFR/ALK/ROS1/PD-L1 testing). Account-network landscape: US Oncology / OneOncology and academic-center structure. Field-model and IC recommendations are framework-derived (specialist-oncology archetype), not a specific company's deployment.
What this analysis answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • Account-tiering logic (academic centers · large community-oncology networks · long-tail) mapped to coverage intensity • Why NSCLC rewards account depth over prescriber breadth
Delivers
- • KAM coverage of practice economics / site-of-care vs. access-and-hub support for oral targeted agents • Where MSL effort concentrates (biomarker testing, guideline positioning)
Delivers
- • Driving comprehensive EGFR/ALK/ROS1/PD-L1 testing as the volume unlock • Positioning within the tested subpopulation vs. chasing untested reach
Custom analysis delivered in 72 hours.
Commission This AnalysisWhat's inside
- Why roughly 13,000 practicing US oncologists and hematologists (ASCO estimate) form a small, identifiable, concentrated target list
- How volume concentrates in a minority of high-volume thoracic-oncology accounts within academic centers and large community networks
- How academic cancer centers, large community-oncology networks such as US Oncology and OneOncology, and long-tail accounts should be tiered
- Why NSCLC commercial success rewards account depth and penetration over prescriber breadth
- Why infused immuno-oncology and chemotherapy are reimbursed as buy-and-bill under Medicare Part B while oral targeted agents route to Part D
- How field roles must cover both the practice-economics conversation and the pharmacy-access conversation across these two channels
- Why EGFR, ALK, ROS1 and PD-L1 testing, per the NCCN NSCLC guideline, determines patient eligibility before any targeting can occur
- How MSL effort concentrates on driving comprehensive biomarker testing rather than broad, untested prescriber reach
- How a workload-based sizing engine converts accounts, call frequency and rep capacity into an FTE and territory design output
- Why account-based KAM plus MSL coverage, not a primary-care-style field force, is the structurally correct deployment model
- What sequence of account tiering, channel coverage and biomarker-testing enablement moves the field model from design to launch
- How incentive compensation should weight account-level testing-rate and site-of-care metrics alongside straight volume
Included with every brief
How AXLRx builds this analysis
Prepared by MoatRx analysts.
AXLRx field-force strategy is built from verifiable commercial-structure inputs: prescriber universe (workforce data), reimbursement channel (CMS), site-of-care and account networks, and biomarker/eligibility gating (guidelines), not from generic sales-force templates. Deployment and sizing recommendations are derived through the field-force methodology and clearly separated from the verified inputs.
US NSCLC sources: ASCO oncology-workforce data, CMS Part B/D reimbursement structure, NCCN NSCLC guideline (biomarker testing), and the US community/academic oncology-network landscape. The full commissioned model adds a workload-based sizing engine (accounts × frequency × capacity → FTE) and territory design.
- Prescriber concentration (~13,000 US oncologists; specialist, not primary-care) attributed to ASCO oncology-workforce estimates — a directional workforce figure.
- Buy-and-bill Part B channel for infused IO/chemo vs Part D for oral targeted agents verified against CMS Part B/Part D structure.
- Biomarker-gated targeting (EGFR/ALK/ROS1/PD-L1) verified against the NCCN NSCLC guideline.
- Field-force size (FTE) is not stated on this page — it is a workload-model output delivered in the commissioned model; this page shows the verifiable structural drivers only.
Frequently asked questions
Commission this analysis
AXLRx delivers US NSCLC field-force strategy built for commercial and sales-operations teams. Custom analysis in 72 hours.
Use the intake form to specify your asset, accounts, and geography.
AXLRx analyst confirms scope, target accounts, and deliverables.
Research-verified analysis in 72 hours with optional analyst readout.